7.12
price up icon0.00%   0.00
after-market 시간 외 거래: 7.15 0.03 +0.42%
loading

Solid Biosciences Inc 주식(SLDB)의 최신 뉴스

pulisher
Mar 19, 2026

Sentiment Recap: Whats the beta of Solid Biosciences Inc stock2026 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn

Mar 19, 2026
pulisher
Mar 19, 2026

Solid Biosciences (SLDB) Strengthens Financial Position with Inc - GuruFocus

Mar 19, 2026
pulisher
Mar 19, 2026

Solid Biosciences (NASDAQ: SLDB) resale registration for 42.8M shares - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

[S-3] Solid Biosciences Inc. Shelf Registration Statement | SLDB SEC FilingForm S-3 - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Solid Biosciences Reports Positive Interim Data for SGT-003 and Advances Clinical Programs in Duchenne Muscular Dystrophy, Friedreich’s Ataxia, and CPVT - Quiver Quantitative

Mar 19, 2026
pulisher
Mar 19, 2026

Solid targets Phase 3 Duchenne dosing in April after positive data - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Gene therapy pipeline at Solid Biosciences (NASDAQ: SLDB) targets Duchenne and cardiac disease - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Solid Biosciences Inc. spotlights leadership role in Friedreich ataxia research collaboration - Traders Union

Mar 19, 2026
pulisher
Mar 18, 2026

Geopolitics Watch: What analysts say about Solid Biosciences Inc stockWeekly Trade Review & Reliable Entry Point Alerts - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 17, 2026

PERCEPTIVE ADVISORS LLC Increases Stake in Solid Biosciences Inc - GuruFocus

Mar 17, 2026
pulisher
Mar 17, 2026

RA Capital boosts Solid Biosciences (SLDB) ownership to 9.9% with March buys - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

H.C. Wainwright Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail

Mar 17, 2026
pulisher
Mar 17, 2026

Solid Biosciences reports interim data from Duchenne gene therapy trial - Investing.com Nigeria

Mar 17, 2026
pulisher
Mar 16, 2026

Citizens reiterates Solid Biosciences stock rating on trial data By Investing.com - Investing.com Canada

Mar 16, 2026
pulisher
Mar 15, 2026

Boxer Capital Management LLC Takes Position in Solid Biosciences Inc. $SLDB - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB - MarketBeat

Mar 15, 2026
pulisher
Mar 14, 2026

Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Korro Bio (KRRO) and Pharming Group (PHAR) - The Globe and Mail

Mar 14, 2026
pulisher
Mar 13, 2026

Friedreich Ataxia research spotlight as Solid Biosciences advances SGT-212 clinical trials - Traders Union

Mar 13, 2026
pulisher
Mar 13, 2026

Options Flow: What analysts say about Solid Biosciences Inc stockExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn

Mar 13, 2026
pulisher
Mar 12, 2026

Solid Biosciences reports interim data from Duchenne gene therapy trial By Investing.com - Investing.com Australia

Mar 12, 2026
pulisher
Mar 12, 2026

Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start (NASDAQ:SLDB) - Seeking Alpha

Mar 12, 2026
pulisher
Mar 12, 2026

Solid Biosciences says interim results reinforce confidence in SGT-003 potential - Yahoo Finance

Mar 12, 2026
pulisher
Mar 12, 2026

SLDB: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus

Mar 12, 2026
pulisher
Mar 12, 2026

Truist reiterates Buy on Solid Biosciences stock after trial data By Investing.com - Investing.com South Africa

Mar 12, 2026
pulisher
Mar 12, 2026

Truist reiterates Buy on Solid Biosciences stock after trial data - Investing.com

Mar 12, 2026
pulisher
Mar 12, 2026

Chardan Capital Reaffirms "Buy" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

Solid Biosciences (SLDB): Chardan Capital Maintains Buy Rating w - GuruFocus

Mar 12, 2026
pulisher
Mar 12, 2026

Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data - TipRanks

Mar 12, 2026
pulisher
Mar 12, 2026

Barclays Maintains Solid Biosciences (SLDB) Overweight Recommendation - MSN

Mar 12, 2026
pulisher
Mar 11, 2026

Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences (NASDAQ: SLDB) reports promising SGT-003 Duchenne data - Stock Titan

Mar 11, 2026
pulisher
Mar 11, 2026

Perceptive invests $49.9M via warrants in Solid Biosciences (SLDB) - Stock Titan

Mar 11, 2026
pulisher
Mar 11, 2026

Perceptive Life Sciences fund acquires 8.9M SLDB pre-funded warrants in Solid Biosciences (SLDB) - Stock Titan

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences (SLDB) Shares Drop After New Trial Data Releas - GuruFocus

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences (NASDAQ:SLDB) Shares Down 6.3%Time to Sell? - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences shares fall after gene therapy trial data - Investing.com

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Bio falls amid new trial data for Duchenne drug - Seeking Alpha

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences shares fall after gene therapy trial data By Investing.com - Investing.com India

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences (SLDB) Reveals Encouraging Interim Data from S - GuruFocus

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences Inc. unveils positive interim data from Duchenne gene therapy trial - Traders Union

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences Reports Positive Interim Data from Phase 1/2 INSPIRE DUCHENNE Trial of SGT-003, Demonstrating Robust Microdystrophin Expression and Encouraging Safety Profile - Quiver Quantitative

Mar 11, 2026
pulisher
Mar 11, 2026

Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Gene therapy from Solid Biosciences shows muscle, heart gains in Duchenne children - Stock Titan

Mar 11, 2026
pulisher
Mar 11, 2026

Wedbush Reiterates Outperform Rating for SLDB with $14 Price Tar - GuruFocus

Mar 11, 2026
pulisher
Mar 11, 2026

Wedbush Reaffirms "Outperform" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Big Money Moves: Will Solid Biosciences Inc stock recover after earnings2026 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn

Mar 11, 2026
pulisher
Mar 10, 2026

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - Bitget

Mar 10, 2026
pulisher
Mar 10, 2026

Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN

Mar 10, 2026
pulisher
Mar 10, 2026

Bain Capital Life Sciences (SLDB) caps Solid Biosciences stake at 9.99% after PIPE - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

RA Capital details 9.9% Solid Biosciences (SLDB) ownership position - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT - MSN

Mar 10, 2026
pulisher
Mar 09, 2026

Solid Biosciences Secures $240 Million in Private Placement - Global Legal Chronicle

Mar 09, 2026
pulisher
Mar 09, 2026

SLDB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 09, 2026
pulisher
Mar 09, 2026

Solid Biosciences (NASDAQ:SLDB) Reaches New 1-Year HighShould You Buy? - MarketBeat

Mar 09, 2026
pulisher
Mar 07, 2026

Solid Biosciences Announces $240 Million Private Placement Financing - The Globe and Mail

Mar 07, 2026
pulisher
Mar 07, 2026

Solid Biosciences secures $240M private placement funding By Investing.com - Investing.com Canada

Mar 07, 2026
pulisher
Mar 06, 2026

Solid Biosciences Raises $240 Million in Private Placement of Stock and Pre-Funded Warrants - TradingView

Mar 06, 2026
$99.29
price up icon 1.20%
$27.80
price up icon 0.00%
$52.37
price down icon 0.06%
$89.31
price down icon 0.77%
$144.00
price up icon 0.91%
biotechnology ONC
$282.72
price up icon 0.15%
자본화:     |  볼륨(24시간):